Genetic and Molecular Abnormalities in Tumors of the Bone and Soft Tissues
Open Access
- 1 May 2001
- journal article
- research article
- Published by SAGE Publications in Cancer Control
- Vol. 8 (3) , 239-251
- https://doi.org/10.1177/107327480100800304
Abstract
Malignant transformation requires the accumulation of multiple genetic alterations such as chromosomal abnormalities, oncogene activation, loss of tumor suppressor genes, or abnormalities in genes that control DNA repair and genomic instability. Sarcomas are a heterogeneous group of malignant mesenchymal tumors of difficult histologic classification and strong genetic predisposition. This article provides a comprehensive review of the cytogenetic abnormalities observed in bone and soft-tissue tumors, emphasizing known downstream molecular changes that may play a role in oncogenesis. The database of the National Library of Medicine was searched for literature relating to genetic and molecular mechanisms in sarcomas in general and in each of the main tumor entities. Recent techniques in chromosome analysis and molecular cytogenetics have improved our ability to characterize genetic changes in mesenchymal tumors. Some changes are so characteristic as to be virtually pathognomonic of particular histologic types, while others are complex, difficult to characterize, and of unknown relevance to pathogenesis. The implications to the cell of some of these abnormalities are now being recognized. The study of sarcomas will benefit from the information derived from genetic studies and translational research. The human genome project and new methodologies, such as computer-based DNA microarray, may help in the histogenetic classification of sarcomas and in the identification of molecular targets for therapy.Keywords
This publication has 59 references indexed in Scilit:
- Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHROncogene, 2000
- Association of EWS-FLI1 Type 1 Fusion with Lower Proliferative Rate in Ewing's SarcomaThe American Journal of Pathology, 2000
- PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcomaOncogene, 1999
- Diminished G1 Checkpoint after γ-Irradiation and Altered Cell Cycle Regulation by Insulin-like Growth Factor II OverexpressionPublished by Elsevier ,1999
- Translocation 2;11 in a fibroma of tendon sheathHistopathology, 1998
- The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumourNature Genetics, 1997
- EWS-FLI-1 andEWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumorInternational Journal of Cancer, 1995
- Molecular Sublocalization and Characterization of the 11;22 Translocation Breakpoint in a Malignant Rhabdoid TumorGenomics, 1994
- Translocation t(12;22)(q13;q12.2–12.3) in a clear cell sarcoma of tendons and aponeurosesGenes, Chromosomes and Cancer, 1993
- Amplification of the c-myc Proto-oncogene in Human ChondrosarcomaDiagnostic Molecular Pathology, 1992